GPCR

Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management - Slideshow (NASDAQ:GPCR) 2026-09-09

Structure Therapeutics: The Amylin Data Changes The Math (NASDAQ:GPCR)

Greene Concepts Highlights Non-Dilutive Capital Structure and Progress Toward Working Capital Financing

Structure Therapeutics Advances Weight-Loss Pills With New Clinical Data

Structure Therapeutics falls after trial data for lead obesity drugs

Jefferies raises Structure Therapeutics stock target on amylin data

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

Structure Therapeutics - A Strong Bet For An Oral GLP-1 Approval Before 2030 (NASDAQ:GPCR)

Structure Therapeutics, Inc. Sponsored ADR Actuals & Estimates (NASDAQ:GPCR)

GPCR Forecast — Price Target — Prediction for 2027

Structure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade) (GPCR)

H.C. Wainwright cuts Structure Therapeutics stock price target to $70

Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron

Does Phase 2b Oral GLP-1 Data on Aleniglipron Change The Bull Case For Structure Therapeutics (GPCR)?